50 related articles for article (PubMed ID: 22192846)
1. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.
An SJ; Yoon YK; Kothari S; Kim DR; Kim JA; Kothari N; Lee E; Park TH; Carbis R
Vaccine; 2012 Feb; 30(6):1023-8. PubMed ID: 22192846
[TBL] [Abstract][Full Text] [Related]
2. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
[TBL] [Abstract][Full Text] [Related]
3. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.
Staats HF; Kirwan SM; Whisnant CC; Stephenson JL; Wagener DK; Majumder PP
Clin Vaccine Immunol; 2010 Mar; 17(3):412-9. PubMed ID: 20107010
[TBL] [Abstract][Full Text] [Related]
4. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
[TBL] [Abstract][Full Text] [Related]
5. A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines.
Alugupalli KR
Front Immunol; 2024; 15():1383476. PubMed ID: 38799439
[TBL] [Abstract][Full Text] [Related]
6. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report.
Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
BMC Pediatr; 2020 Oct; 20(1):480. PubMed ID: 33059607
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
[TBL] [Abstract][Full Text] [Related]
8. Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi.
Acevedo R; Callicó A; Aranguren Y; Zayas C; Valdés Y; Pérez O; García L; Ferro VA; Pérez JL
BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S10. PubMed ID: 23458379
[TBL] [Abstract][Full Text] [Related]
9. Immune response of S. Typhi-derived Vi polysaccharide and outer membrane protein a conjugate in mice.
Haque S; Sengupta S; Khan A; Mukhopadhyay AK; Bhan MK; Kumar R; Jailkhani B
Pediatr Neonatol; 2023 Sep; 64(5):518-527. PubMed ID: 36868948
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.
Tamrakar D; Poudel P; Thapa P; Singh S; Khadgi A; Thapa S; Tamrakar R; Shrestha A; Madhup S; Rai GK; Gupta BP; Saluja T; Sahastrabuddhe S; Shrestha R
Hum Vaccin Immunother; 2024 Dec; 20(1):2301631. PubMed ID: 38189360
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of Vi-diphtheria toxoid typhoid conjugate vaccine among children below 2 years: a systematic review and meta-analysis.
Mohamed Taha A; Abouelmagd K; Mahmoud AM; Elkasaby MH; Nguyen D; Ahmed R; Patel P; Bonilla-Aldana DK; Luna C; Rodriguez-Morales AJ
Front Microbiol; 2024; 15():1385834. PubMed ID: 38646637
[TBL] [Abstract][Full Text] [Related]
12. WITHDRAWN: Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF;
Biologicals; 2018 Jun; ():. PubMed ID: 29941335
[No Abstract] [Full Text] [Related]
13. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
14. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
[TBL] [Abstract][Full Text] [Related]
15. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.
Jossi SE; Arcuri M; Alshayea A; Persaud RR; Marcial-Juárez E; Palmieri E; Di Benedetto R; Pérez-Toledo M; Pillaye J; Channell WM; Schager AE; Lamerton RE; Cook CN; Goodall M; Haneda T; Bäumler AJ; Jackson-Jones LH; Toellner KM; MacLennan CA; Henderson IR; Micoli F; Cunningham AF
Front Immunol; 2023; 14():1139329. PubMed ID: 37033932
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus spike protein ΔVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine.
Park WJ; Yoon YK; Park JS; Pansuriya R; Seok YJ; Ganapathy R
Sci Rep; 2021 Nov; 11(1):22037. PubMed ID: 34764353
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
Capeding MR; Alberto E; Sil A; Saluja T; Teshome S; Kim DR; Park JY; Yang JS; Chinaworapong S; Park J; Jo SK; Chon Y; Yang SY; Ham DS; Ryu JH; Lynch J; Kim JH; Kim H; Excler JL; Wartel TA; Sahastrabuddhe S
Vaccine; 2020 Jun; 38(28):4476-4483. PubMed ID: 31585725
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
[TBL] [Abstract][Full Text] [Related]
19. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
